Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

@article{Cherney2017EffectsOE,
  title={Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.},
  author={D. Cherney and B. Zinman and Silvio E. Inzucchi and A. Koitka‐Weber and M. Mattheus and M. von Eynatten and C. Wanner},
  journal={The lancet. Diabetes & endocrinology},
  year={2017},
  volume={5 8},
  pages={
          610-621
        }
}
  • D. Cherney, B. Zinman, +4 authors C. Wanner
  • Published 2017
  • Medicine
  • The lancet. Diabetes & endocrinology
  • BACKGROUND In a pooled analysis of short-term trials, short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria. In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease, according to patients' baseline albuminuria status… CONTINUE READING
    OP-NDTJ180031 1942..2019
    • 2018

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 40 REFERENCES